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Columnar cell lesions and subsequent breast
cancer risk: a nested case-control study
Sarah A Aroner1*, Laura C Collins2, Stuart J Schnitt2, James L Connolly2, Graham A Colditz3, Rulla M Tamimi1,4

Abstract
Introduction: Histologic and genetic evidence suggests that at least some columnar cell lesions (CCL) of the
breast represent precursor lesions in the low-grade breast neoplasia pathway. However, the risk of subsequent
breast cancer associated with the presence of CCL in a benign breast biopsy is poorly understood.
Methods: The authors examined the association between the presence of CCL and subsequent breast cancer risk
in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses’ Health Studies
(394 cases, 1,606 controls). Benign breast biopsy slides were reviewed by pathologists and CCL presence assessed.
Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the association
between CCL and breast cancer risk.
Results: Women with CCL (140 cases, 448 controls) had an increased risk of breast cancer compared with those
without CCL (OR = 1.44, 95% CI: 1.14 to 1.83), although this was attenuated and became non-significant after
adjustment for the histologic category of BBD (OR = 1.20, 95% CI: 0.94 to 1.54). CCL presence was associated with
the greatest risk of breast cancer for those with nonproliferative BBD (OR = 1.36, 95% CI: 0.79 to 2.37) and the
lowest risk for those with atypical hyperplasia (AH) (OR = 1.10, 95% CI: 0.65 to 1.87); however, this apparent
heterogeneity in risk across BBD categories was not significant (P for interaction between CCL presence and BBD
category = 0.77).
Conclusions: These results provide evidence that CCL may be an important marker of breast cancer risk in women
with BBD but suggest that CCL do not increase breast cancer risk independently of concurrent proliferative
changes in the breast.

Introduction
With the widespread adoption of screening mammography in the past several decades, columnar cell lesions
(CCL) of the breast have become a frequent finding in
breast biopsies. In fact, these lesions have been reported
to be present in nearly half of biopsies performed for
mammographic microcalcifications and have been identified as the source of three-quarters of biopsy-detected
microcalcifications [1]. CCL is a broad designation that
encompasses a wide range of histologic changes ranging
from alterations of the epithelium with no architectural
or cytologic atypia to changes resembling ductal carcinoma in situ (DCIS) [2]. Although these lesions have
been recognized for some time, the diverse terminology
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used to describe such lesions has hindered the understanding of their clinical significance. The myriad of
names used to describe these lesions include “blunt duct
adenosis” [3,4], “clinging carcinoma” [5,6], “columnar
alteration with prominent apical snouts and secretions”
[1], “atypical ductal cells with apocrine snouts” [7],
“atypical cystic lobules” [8-10], and “well-differentiated
DCIS with a clinging architecture” [11]. The increasing
use of the term “columnar cell lesions” and the standardization of the classification scheme for these lesions [2]
is facilitating the study of CCL as a potential breast cancer risk factor.
Some of the earliest evidence suggesting that CCL
may be premalignant was their frequent detection near
known precancerous and cancerous changes in the
breast. Several studies have reported a high frequency of
CCL and low-grade DCIS in the same breast [1,8,12],
with concurrent CCL and DCIS commonly occurring in
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the same or adjacent terminal duct lobular units [1]. Cooccurrence of CCL and low-grade invasive carcinomas,
particularly tubular carcinoma, has also been observed
[7,13-16]. The presence of CCL in proximity to invasive
and non-invasive breast cancer suggests that CCL may
have the potential to undergo malignant transformation,
although CCL may simply be markers for other precancerous conditions in the breast.
Mounting histopathologic and molecular evidence
indicates that CCL may indeed be early precursors to
low-grade invasive breast carcinomas. CCL have been
proposed as breast cancer precursors largely because of
the cytologic and architectural similarities of more
advanced CCL to atypical hyperplasia (AH), a suspected
precancerous abnormality, and DCIS, a well-established
precursor to invasive carcinoma [1,8,10]. In many cases,
the cellular features of advanced CCL so closely resemble those of low-grade DCIS that the distinction
between the two lesions can be challenging [1,8].
Genetic alterations in CCL following a similar progression as the morphological changes have also been
observed, and the mutations in the most advanced
lesions have been found to be very similar to those in
DCIS or invasive cancer [17-19]. Supporting these findings is evidence of an immunophenotypic link between
CCL and breast carcinoma, with advanced CCL displaying an immunohistochemical profile similar to that of
DCIS and low-grade invasive cancer [8,18,20-22].
Descriptive studies among patients with advanced
CCL, although unable to quantify the elevation in breast
cancer risk associated with CCL, suggest that CCL are
unlikely to be a strong risk factor for subsequent breast
cancer. While Martel et al. did find some suggestion of
an increased risk of breast cancer subsequent to CCL, as
9 out of 63 participants with advanced CCL (14.3%)
developed subsequent infiltrating carcinomas after eight
years of follow-up [23], most other descriptive studies
have found little evidence for an association between
CCL and subsequent breast cancer. In fact, De Mascarel
et al. found that none of 84 patients with advanced CCL
alone developed subsequent breast cancer over a 10-year
follow-up [24]. Similarly, no cases of invasive breast cancer were found among 59 patients with CCL followed
for a median of 5.4 years in the European Organization
for Research and Treatment of Cancer randomized clinical trial [11] or among 25 patients with CCL followed
for 19.2 years in a retrospective analysis by Eusebi et al.
[6]. Although these descriptive studies have provided
insight into the natural history of BBD, most were limited by their small sample sizes and short follow-up, and
their absence of a comparison group without CCL precludes assessment of the risk associated with CCL.
The very limited epidemiologic evidence on CCL suggests that CCL may be markers for concurrent atypical
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proliferative changes in the breast rather than breast
cancer precursors [25-27]. Given the scarcity of epidemiologic data on the nature of these lesions, we undertook a study of CCL in relation to breast cancer risk
using data from an established case-control study of
benign breast disease (BBD) within the Nurses’ Health
Study (NHS) and the Nurses’ Health Study II.

Materials and methods
Study population

The NHS is an ongoing prospective cohort study that
began in 1976, when 121,700 female registered nurses
between ages 30 and 55 years completed a mailed, selfadministered questionnaire regarding their health behaviors, lifestyle factors, and medical histories. Follow-up
questionnaires have been sent to participants every two
years to obtain updated information. The biennial questionnaires have assessed a variety of known and suspected risk factors for breast cancer, including history of
BBD. On the 1976, 1978, and 1980 questionnaires, participants were asked if they had ever been diagnosed with
fibrocystic or other BBD and whether this diagnosis had
required hospitalization; from 1982 onward, the questionnaires have inquired specifically about BBD confirmed by biopsy. Deaths are reported by family
members and the postal service, and regular searches of
the computerized National Death Index are also conducted [28]. The NHS II is a separate cohort study consisting of 116,609 female registered nurses who were
between the ages of 25 and 42 years when the study
began in 1989. The follow-up methods used in this
cohort are very similar to those for the original NHS.
On each biennial questionnaire, participants have been
asked if they have ever been diagnosed with BBD and, if
yes, whether the diagnosis was confirmed by biopsy or
aspiration. The follow-up rate for each two-year cycle
has been greater than 90% of the original cohorts.
We conducted a nested case-control study to assess
morphological changes in benign breast lesions and
breast cancer risk among participants in the NHS and
NHS II who had reported a previous diagnosis of BBD
that was confirmed by biopsy. Within this subcohort,
eligible cases were women who reported a first diagnosis
of breast cancer between 1976 and the return of the
1996 questionnaire in the NHS or between 1989 and
return of the 1995 questionnaire in the NHS II. Selfreported breast cancers were confirmed by review of
medical records, and both invasive breast cancer and
carcinoma in situ were included in the study. Eligible
controls were women who completed the questionnaire
for the same year that the breast cancer case was
reported and had a previous diagnosis of biopsy-confirmed BBD, but were free from breast cancer; within
each NHS cohort, they were matched to breast cancer
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cases on year of birth and year of diagnosis of BBD. We
attempted to identify four matched controls for each
case, but this was not always possible for logistical reasons. Informed consent was obtained from all participants. The study was approved by the Human Research
Committee of Brigham and Women’s Hospital, Boston,
Massachusetts.
Benign breast biopsy specimens

Eligible cases and controls were contacted for permission to obtain their BBD pathology records and biopsy
specimens, and specimens then were obtained from hospital pathology departments when possible. These methods have been described in detail elsewhere [29,30].
Briefly, >70% of the 1,310 cases and 5,273 controls who
originally were identified for the study confirmed the
diagnosis and granted permission, and specimens subsequently were obtained for 52% of those who had granted
their permission (465 cases and 1,939 controls). The primary reason given by hospital pathology departments
for not sending specimens was that they had been
destroyed or were no longer available (35%) [29,30].
Biopsy slides were independently reviewed by one of
two study pathologists (SJS, JLC) who were blinded to
the participants’ case or control status. The pathologists
completed a detailed worksheet with information on the
morphologic features of each specimen, and biopsies
were then classified as nonproliferative, proliferative
without atypia, or AH, according to the criteria of Page
et al. [31,32], which have been used in previous investigations in this cohort [29,33,34]. All biopsies, including
bilateral biopsies, were classified according to the most
severe changes present, and specimens with possible or
definite AH were jointly reviewed by both pathologists.
After excluding participants whose benign biopsy specimens were of poor quality or had no breast tissue, evidence of carcinoma in situ or invasive carcinoma,
invalid dates of diagnosis, or insufficient information on
laterality, there were a total of 395 cases and 1,610 controls [29,30]. Although we were successful in obtaining
slides for only 30% of those originally identified, the success rate did not differ significantly between those with
a subsequent breast cancer diagnosis and those without.
In addition, the breast cancer risk factors for women
from whom we were successful in obtaining pathology
specimens were very similar to those for the women for
whom we were unable to obtain specimens, suggesting
that these women were missing at random.
During histologic review of benign breast biopsies for
breast cancer cases reported in the 1976 through 1996
questionnaires in the NHS and in the 1991 through
1995 questionnaires in the NHS II and for matched controls, the presence of CCL was recorded on the pathology worksheets as “columnar alteration of lobules.” At
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the time these benign breast biopsies were reviewed,
CCL were not considered to be of particular interest
and were usually not further stratified; thus, the categorization of these lesions as “columnar alteration of
lobules” was in keeping with the standard of practice of
the time. For the 42 cases and 116 controls from the
NHS 1996 questionnaire cycle, presence of CCL subtypes (columnar cell change, columnar hyperplasia, and
flat epithelial atypia) was assessed rather than the overall
presence of CCL. These women with only subtype information were re-categorized by presence or absence of
CCL to allow their inclusion in analyses. After exclusion
of five subjects having lesions without adjacent tissue
for evaluation, the final sample for this analysis included
394 cases and 1,606 controls. Given the small number
of cases and controls in which CCL were further classified with regard to the presence or absence of atypia,
CCL were considered as a single group for these
analyses.
Statistical analysis

The distributions of breast cancer risk factors were
examined according to CCL presence among the controls, adjusting for age at benign biopsy when appropriate. Unconditional logistic regression was used to
estimate odds ratios (ORs) and 95% confidence intervals
(95% CIs) for breast cancer risk according to CCL presence. Unconditional rather than conditional logistic
regression was used because this analytic approach
allowed us to use all cases and controls for whom we
had histologic information. We first adjusted only for
the matching factors, which were age at breast cancer
diagnosis or index date (<45 years, 45 to 49 years, 50 to
54 years, 55 to 59 years, ≥60 years), year of benign
breast biopsy (before 1970, 1970 to 1979, 1980 to 1989,
1990 and later), and time since benign biopsy (years
from BBD diagnosis to the breast cancer diagnosis or
index date, as a continuous variable). In another set of
models, additional adjustment was made for histologic
category of BBD (nonproliferative, proliferative without
atypia, or AH), which is a strong predictor of breast
cancer risk [31]. We also jointly classified women
according to histologic category and CCL presence to
examine whether the association of CCL with breast
cancer risk differed by category of BBD; a likelihood
ratio test was used to test for interaction.
The following covariates were considered as potential
confounding factors: first-degree family history of breast
cancer (yes, no), age at menarche (<12 years, 12 years, 13
years, ≥14 years), menopausal status (premenopausal,
postmenopausal, dubious/unsure), jointly classified parity
and age at first birth (nulliparous, 1 to 2 children and <25
years, 1 to 2 children and 25 to 29 years, 1 to 2 children
and ≥30 years, ≥3 children and <25 years, ≥3 children and
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≥25 years), BMI at age 18 (<21, 21 to 22.9, 23 to 24.9,
25+ kg/m2), postmenopausal hormone use (premenopausal, postmenopausal never, ever), and oral contraceptive
use (never, ever). Because BMI at age 18 appeared to be
more strongly related to breast cancer risk than current
BMI, we chose to consider adjustment for BMI at age 18
and change in weight since age 18 rather than current
BMI. Individual adjustment for these covariates did not
change the estimated OR substantially, nor did simultaneous adjustment for the four factors having the strongest
influence on the OR (BMI at age 18, family history of
breast cancer, postmenopausal hormone use, and jointly
classified parity/age at first birth). We examined relationships between CCL and estrogen receptor (ER) status,
grade, and ipsilaterality in additional unconditional logistic
regression models. All statistical analyses were performed
using the SAS software package (version 9.1; SAS Institute,
Cary, NC, USA). All tests were two-sided, with P < 0.05
indicating statistical significance.

Results
The mean age at benign breast biopsy among all participants was 43.7 years (SD = 10.0 years), and the mean
time since biopsy was 10.0 years (SD = 7.2 years). Compared with women with no CCL, women with CCL
were older at the time of their biopsy and had less time
since their biopsies (Table 1). Women with and without
CCL were generally similar with regard to their distribution of breast cancer risk factors, although women with
CCL were slightly leaner than those without CCL and
were less likely to have used postmenopausal hormones.
Histologic subtype of BBD was strongly associated with
presence of CCL, with women having CCL much more
likely to have proliferative disease and AH compared
with women without CCL (P < 0.0001). We also
assessed breast cancer risk factors by case-control status
and found that established breast cancer risk factors
were associated with breast cancer in our study population, although most of these associations were non-significant. Compared with controls, cases had a higher
prevalence of family history of breast cancer, lower
mean parity and older mean age at first birth among
parous women, higher mean alcohol consumption, and
a higher prevalence of postmenopausal hormone use
(see Supplementary table S1 in Additional file 1).
In the multivariate logistic regression models controlling for matching factors only (Table 2), women with
CCL had a significantly higher risk of breast cancer
compared with those without CCL (OR = 1.44; 95% CI,
1.14 to 1.83). However, after additional adjustment for
histologic category of benign breast disease, this association became non-significant (OR = 1.20; 95% CI, 0.94 to
1.54). These associations were very similar when only
invasive breast cancer cases were included (OR = 1.44;
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Table 1 Characteristics by CCL status among controls
with BBD*
No. of controls (%)

CCL

No CCL

448
(27.9)

1,158
(72.1)

Means
Age at BBD biopsy, years

45.1

43.3

Year of BBD biopsy (median)
Time since BBD biopsy, years

1979
9.3

1979
10.1

No. of BBD biopsy slides†

5.7

5.5

Body mass index, kg/m2†

24.2

25.0

Body mass index at age 18, kg/m2†

20.5

21.1

Weight gain after age 18, kg†

10.0

10.7

Age at menarche, years†

12.7

12.6

Age at first birth, years (parous only)†

24.9

24.9

Alcohol intake, g/day†
Parity (parous only)†

4.2
3.0

4.0
3.0

Premenopausal†

36.0

35.5

Parous†

91.9

92.4

First degree family history of breast
cancer†

19.0

17.6

Ever postmenopausal hormone use†

32.0

37.3

Ever oral contraceptive use†

45.1

49.6

Nonproliferative
Proliferative without atypia

21.5
61.8

44.4
48.4

Atypical hyperplasia

16.8

7.2

Percentages

Histologic category of BBD†

CCL indicates columnar cell lesions; BBD, benign breast disease.
*Unless otherwise specified, all variables correspond to the time period
immediately prior to the index date.
†Means and percentages were standardized to the age distribution of the
controls at the time of benign biopsy, in five-year categories.

95% CI, 1.11 to 1.86 with adjustment for matching
factors only and OR = 1.18; 95% CI, 0.90 to 1.55 with
additional adjustment for histologic category of BBD).
When women were jointly classified according to histologic category and CCL presence, all groups had an
elevated breast cancer risk compared with the reference
category, nonproliferative BBD and no CCL. Women
with both AH and CCL were at highest risk (OR = 4.37;
95% CI, 2.81 to 6.81), but this risk was not significantly
different from that among those with AH without CCL.
Within all BBD histologic categories, breast cancer risk
was elevated for women with CCL, with the risk higher
for those with less severe BBD (nonproliferative BBD:
OR = 1.36, 95% CI: 0.79 to 2.37; proliferative BBD without atypia: OR = 1.21, 95% CI: 0.87 to 1.68; and AH:
OR = 1.10, 95% CI: 0.65 to 1.87; adjustment for matching factors only). However, there was no evidence of an
interaction between CCL and BBD histologic category
when either three histologic categories were used
(P = 0.77) or when proliferative disease without atypia
and AH were collapsed into a single category (P = 0.93).
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Table 2 ORs and 95% CIs for CCL and breast cancer risk among participants with BBD
Cases

Controls

OR (95%CI)*

OR (95%CI)**

No CCL

254

1,158

1.0 (reference)

1.0 (reference)

CCL

140

448

1.44 (1.14, 1.83)

1.37 (1.06, 1.76)

No CCL

254

1,158

1.0 (reference)

1.0 (reference)

CCL

140

448

1.20 (0.94, 1.54)

1.16 (0.89, 1.50)

Nonproliferative, no CCL
Nonproliferative, CCL

80
19

518
93

1.0 (reference)
1.33 (0.77, 2.29)

1.0 (reference)
1.24 (0.69, 2.22)

Proliferative without atypia, no CCL

125

558

1.46 (1.08, 1.99)

1.38 (1.00, 1.91)

Proliferative without atypia, CCL

74

277

1.81 (1.27, 2.58)

1.63 (1.12, 2.38)

Atypical hyperplasia, no CCL

49

82

4.26 (2.75, 6.59)

4.04 (2.57, 6.36)

Atypical hyperplasia, CCL

47

78

4.37 (2.81, 6.81)

4.20 (2.63, 6.70)

CCL status

CCL status, adjusted for BBD histologic category

Jointly classified BBD/CCL histologic category

OR indicates odds ratio; 95% CI, 95% confidence interval.
*Adjusted for age, year of BBD diagnosis, and time since BBD biopsy.
**Adjusted for the above-mentioned factors and body mass index at age 18, weight change between age 18 and diagnosis/index date, family history of breast
cancer, postmenopausal hormone use, and jointly classified parity/age at first birth.

There was some suggestion that women with CCL had
a higher risk of ER positive and ipsilateral breast cancer
compared with women without CCL, but these associations were not significant after adjustment for BBD histologic category. Breast cancer grade appeared to be
unrelated to CCL status.

Discussion
Our results in this established nested-case control study
of BBD point to a modestly increased risk of breast cancer among women with CCL. However, it appeared that
most of this elevation in risk was due to the close association between CCL and proliferative disease, which
itself is an established risk factor for subsequent breast
cancer [31]. Despite the apparent lack of an independent
association between CCL and breast cancer, there was
an indication that CCL may influence breast cancer risk
among women with nonproliferative disease.
Few previous epidemiologic analyses have evaluated
the risk of subsequent breast cancer following detection
of CCL, but the magnitude of risk associated with the
presence of CCL found in our study is consistent with
that reported by Boulos et al. in a large retrospective
cohort study among women in the Nashville Breast
Cohort. Similar to our study, the Nashville study found
a nearly 50% elevation in breast cancer risk associated
with CCL (RR = 1.47; 95% CI: 1.0 to 2.2), although this
analysis excluded those with AH, who have been shown
to be at highest risk of subsequent breast cancer. Given
the strong correlation between CCL and concurrent AH
found by Boulos et al. (P < 0.0005), it is possible that
the relative risk for presence of CCL would have been
somewhat higher had women with AH been included in
the main analysis. As in our study, Boulos et al. found

that the elevated risk of breast cancer among those with
AH was not further increased among those who additionally had CCL, suggesting that CCL are not an independent breast cancer risk factor among women with
AH [25]. Another recent analysis by Kabat et al. that
assessed subsequent breast cancer risk from a broad
range of benign breast lesions found a non-significantly
elevated risk of breast cancer among a small number of
women with multiple CCL compared with those with
non-proliferative disease and no breast pathology (RR =
1.72, 95% CI: 0.87 to 3.41), although no increased risk
was found for focal CCL (RR = 0.81, 95% CI: 0.47 to
1.39) [27]. However, it is difficult to compare our results
with those from the study by Kabat et al. because this
study used a different pathologic classification scheme
in which CCL were considered a proliferative disease
rather than a separate entity that could exist in conjunction with either nonproliferative or proliferative BBD.
Our study is the largest nested case-control study of
CCL and breast cancer to date and therefore yields important clues into the relationship between presence of CCL
and breast cancer risk. However, given the heterogeneity
of CCL, it is possible that assessing risk of breast cancer
for all CCL subtypes combined masks an effect of
advanced CCL subtypes, which are less common. Histopathologic and molecular evidence suggests that CCL displaying low-grade cytologic atypia, recently termed “flat
epithelial atypia” (FEA) by the World Health Organization
Working Group on the Pathology and Genetics of Tumors
of the Breast [35], may be a direct precursor to low-grade
DCIS, while the more common non-atypical CCL are not
thought to be precancerous [36].
However, the malignant potential of FEA remains
equivocal, as descriptive and epidemiologic studies fail
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to support molecular findings, just as they do for overall
CCL risk. Most descriptive follow-up studies among
women with what would now be classified as FEA,
including one with an average follow-up of nearly
20 years, have found progression to invasive carcinoma
to be uncommon [6,11,23,24]. Three previous observational studies have assessed CCL subtype-specific risks,
but all had limited power to detect associations for FEA
due to small numbers of women with this subtype. Two
of these studies did find an increased risk among
women with atypical CCL compared with those having
nonproliferative disease [27] or with all women without
atypical CCL [26], but results were non-significant and
confidence intervals were very wide, as one study had
19 women with atypical CCL [26] and the other had
only 6 [27]. The largest of the three studies found no
evidence of an increased breast cancer risk associated
with “columnar cell lesions with atypia” among women
without AH. This study did indicate that risk may be
increased for those having CCL with hyperplasia,
although this could have been a chance finding due to
the small number of women with each CCL subtype
even in this larger analysis [25].
Although we considered performing a CCL subtypespecific analysis, information on subtype (columnar cell
change, columnar hyperplasia, and FEA) was collected
for only 157 women whose breast cancer or index date
was reported on the 1996 NHS questionnaire. We chose
not to re-review the biopsy slides for the presence of
FEA, as prevalence of FEA appeared very low from the
1996 questionnaire cycle, with only 4 of the women out
of 53 with CCL from this cycle having FEA. Because FEA
is a rare occurrence, many thousands of breast biopsies
would be needed for adequate power to study its relationship with subsequent breast cancer. Moreover, to
study the association between FEA and breast cancer
independent of AH, an adequate number of women with
FEA but not AH would be required. This would only be
possible in an extremely large study, as FEA commonly
occurs in conjunction with AH. Even in the largest previous epidemiologic study of CCL by Boulos et al., only
52 biopsies contained FEA without AH [25].
The strengths of the study include its prospective
design, the confirmation of breast cancer cases through
review of medical records, the centralized pathology
review of specimens from benign biopsies before the
development of breast cancer, and the detailed information on other breast cancer risk factors. Furthermore,
ours is the first observational study to compare the risk
of subsequent breast cancer by BBD histologic category.
Although power was limited to test for heterogeneity by
histologic category, our findings suggest that CCL may
be a marker of increased risk among those with nonproliferative disease. Such a differential effect of CCL on
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breast cancer risk across BBD categories could have
important implications for clinical management of
patients with CCL, especially given that women with
non-proliferative disease are typically considered to be
at no elevated risk for breast cancer compared with
women from the general population.

Conclusions
In light of these findings, large epidemiologic studies
assessing CCL subtype-specific risks are needed to
inform clinical guidelines for the management of CCL.
In particular, better understanding is needed as to
whether CCL with atypia in the absence of more
advanced lesions require treatment similar to that for
DCIS. Additionally, adequately powered epidemiologic
studies might help elucidate whether CCL are of concern only among women without proliferative disease.
Regardless of whether particular CCL subtypes are simply markers for premalignant changes in the breast or
precancerous histologic changes themselves, recognition
of these lesions is nevertheless important, as detection
of CCL via biopsy should prompt additional scrutiny for
other pathologic changes in breast tissue that may signal
the early development of DCIS or invasive carcinoma.
Additional material
Additional file 1: Supplementary table S1. A Word document
containing a table that lists the means and percentages of characteristics
by case-control status among participants with benign breast disease
(BBD).
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